 REDWOOD CITY, Calif., April 28, 2021 GLOBE NEWSWIRE -- Adverum Biotechnologies, Inc. Nasdaq: ADVM announced a Suspected Unexpected Serious Adverse Reaction SUSAR of hypotony clinically-relevant decrease in ocular pressure in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema DME. This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose 6 x 1011 vgeye of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye. 